Yongbin Ma
Overview
Explore the profile of Yongbin Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu W, Li L, Bai X, Zhang M, Lv W, Ma Y, et al.
Adv Sci (Weinh)
. 2025 Mar;
:e2409870.
PMID: 40056029
The local tumor microenvironment (TME) of osteosarcoma (OS) includes several tumor niches that control tumor growth and cell extravasation. Migrasomes are recently discovered extracellular vesicles produced during cell migration. Herein,...
2.
Hong X, Ma Y, Yang W, Li Y, Tang X, Wang Z
J Biochem Mol Toxicol
. 2025 Mar;
39(3):e70185.
PMID: 40052404
Metabolic syndrome, primarily driven by high-fat/high-sugar (HF/HS) diets, is closely linked to insulin resistance and renal injury, leading to serious complications such as type 2 diabetes mellitus and diabetic nephropathy....
3.
Gu W, Zheng T, Li W, Luo X, Xu X, Wang Y, et al.
Stem Cell Res Ther
. 2025 Jan;
16(1):26.
PMID: 39865246
Background: Asthma is a prevalent respiratory disease, and its management remains largely unsatisfactory. Mesenchymal stem cells (MSCs) have been demonstrated to be efficacious in reducing airway inflammation in experimental allergic...
4.
Matrine-loaded Nano-liposome Induces Apoptosis in Human Esophageal-squamous Carcinoma KYSE-150 Cells
Zhao K, Cai Y, Raza F, Zafar H, Pan L, Zheng X, et al.
Curr Pharm Des
. 2024 Jul;
30(29):2303-2312.
PMID: 38994614
Introduction: Esophageal-squamous Cell Carcinoma (ESCC) is often diagnosed at the middle or late stage, thus requiring more effective therapeutic strategies. Pharmacologically, the anti-tumor activity of the principal active constituent of...
5.
Ding L, Yuan X, Wang Y, Yang M, Wu P, Chen H, et al.
Asia Pac J Clin Oncol
. 2024 Jun;
20(6):700-706.
PMID: 38898784
Aim: To report the efficacy and safety of ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, in treating patients with ALK-positive advanced lung squamous cell carcinoma (LUSC) or lung adenosquamous carcinoma...
6.
Yuan X, Wang Y, Yang M, Wu P, Chen H, Yun Y, et al.
Lung Cancer Manag
. 2024 Jan;
12(4):LMT61.
PMID: 38239813
Aim: This retrospective study aimed to assess the efficacy and safety of ensartinib in Chinese patients with -positive advanced NSCLC in real-world clinical practice. Methods: Clinical data from -positive NSCLC...
7.
Ma Y, Zhao L, Zhou D, Li T, Feng Y, Yao X, et al.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
. 2023 Dec;
39(12):1069-1073.
PMID: 38140865
Objective To establish an efficient method for isolating migrasomes from RAW264.7 macrophages and identifying these isolated migrasomes. Methods Scanning electron microscopy was used to observe the morphological characteristics of migrasomes...
8.
Qi X, Pu Y, Chen F, Dong L, Ma Y, Wang J, et al.
PLoS Negl Trop Dis
. 2023 May;
17(5):e0011385.
PMID: 37253066
Schistosomiasis is a serious and neglected disease with a high prevalence in tropical and subtropical countries. The primary pathology of hepatic schistosomiasis caused by Schistosoma japonicum (S. japonicum) or Schistosoma...
9.
Jiang Y, Liu X, Ye J, Ma Y, Mao J, Feng D, et al.
Cell Commun Signal
. 2023 May;
21(1):105.
PMID: 37158915
Migrasomes are newly discovered extracellular vesicles (EVs) that are formed in migrating cells and mediate intercellular communication. However, their size, biological generation, cargo packaging, transport, and effects on recipient cells...
10.
Xu X, Wang Y, Luo X, Gao X, Gu W, Ma Y, et al.
Front Immunol
. 2023 Apr;
14:1150971.
PMID: 37090722
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are extremely promising nanoscale cell-free therapeutic agents. We previously identified that intravenous administration (IV) of human umbilical cord MSC-EVs (hUCMSC-EVs), especially hypoxic hUCMSC-EVs (Hypo-EVs),...